Fact CheckerSign in

NCT04353778CompletedPhase 1/2

Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

Source: ClinicalTrials.gov · Last updated 18 Aug 2026

Brief summary (registry, in English)

The study team's prior research has shown that dysfunction of a specific nerve, called the vagus nerve, is associated with small intestinal bacterial overgrowth (SIBO), and that SIBO is associated with signs of inflammation in the blood of people living with HIV (PLWH). This research will explore pathways linking vagal dysfunction to inflammation in HIV, focusing on the gastrointestinal tract, and study whether a medication called pyridostigmine and stimulation of the vagus nerve are beneficial therapies.

Status (registry)
Completed
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
215 (actual)
First submitted
17 Apr 2020
Start date
3 Aug 2020
Primary completion date
27 Mar 2026
Lead sponsor
Icahn School of Medicine at Mount Sinai
Diseases
HIV
NCT number
NCT04353778

What you commit to

  • Study type: Interventional · Phase 1/2
  • Participants enrolled: 215
  • From 3 Aug 2020 to the primary completion date, 27 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Known or suspected obstructive disease of the GI tract (e.g. bezoar, strictures, fistulae, physiologic GI obstruction)
  • GI surgery within 3m, Crohn's disease, diverticulitis, any electromechanical medical device (e.g. pacemaker, infusion pump).
  • Contraindication to pyridostigmine (e.g. mechanical intestinal or urinary obstruction, hypersensitivity to pyridostigmine, cardiac arrhythmias, asthma, chronic obstructive pulmonary disease); use of pyridostigmine within the past 6m.
  • History of intracranial aneurysm/hemorrhage, brain tumor, abnormal neck anatomy, or implants or metal hardware near site of stimulation; exposure to VNS within the past 6m.

Other

  • Dysphagia to food or pills

Who the study is looking for

  • Greater than or equal to18 years old (18 to 64 Years, 65 Years and Over)
  • Documentation of HIV-1 infection
  • Stable CART for greater or equal to 3 months
  • HIV-1 viral load \<100 copies/ml (within 3m)
  • No diagnosis known to cause autonomic or GI dysfunction other than HIV (e.g. Parkinson's disease, diabetes, peptic ulcer disease, infectious diarrhea)
  • Willing to refrain from nicotine use for 24h prior to all testing
  • No contraindication to autonomic testing (e.g. uncontrolled glaucoma, heart rate not under sinus control)
  • No medications with significant autonomic or GI effects (e.g. sympathomimetics, prokinetics, anti-diarrheals, antibiotics)
  • Urine test negative for stimulants and opiates/opioids and pregnancy test (if applicable)

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Icahn School of Medicine at Mount Sinai
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.